Celiac disease is a chronic illness of the small intestinal mucous membrane. The reason is an intolerance against gluten, which is found in many cereals. This food intolerance against cereal proteins leads to a production of auto-antibodies against tissue transglutaminase, which is the major antigen for endomysium antibodies.
The intake of gluten-containing food leads to an inflammation of the small intestinal mucous membrane. The resorption of nutrients is reduced. The symptoms of the disease are reduction of weight, diarrhoea, vomitus, anorexia and tiredness. The growth of children is reduced. The characteristic of the symptoms might be different. The only therapeutic treatment is a gluten-free diet. A non-treated celiac disease increases the risk of non-Hodgkin-lymphoma and colon cancer. In five to ten percent of the patients celiac disease is associated with diabetes mellitus typ 1. Women are more often affected than men. The outcome of the disease is pronounced during infancy and in an age between 30 and 40 years.
Sample volume 100 mg, 100 µl
Calibration 5 point
Incubation time 1h, 1h, 15 min
Principle of the method
The anti-tissue transglutaminase-ELISA test determines anti-tissue transglutaminase sIgA / IgA antibodies according to the “sandwich”-principle. Anti-tissue transglutaminase antibodies in sample, standard and controls bind to tissue transglutaminase, which is coated to the microtiterplate. After a washing step a peroxidase labeled detection antibody is added. A second washing step is followed by the addition of the substrate which is converted to a colored product by the peroxidase. The reaction is terminated by the addition of an acidic stop solution. The optical densities are measured at 450 nm in a microtiterplate reader. The anti-tissue transglutaminase concentration can be calculated from the standard curve.